Nymox Pharmaceutical Corp (NYMX)

2.09
NASDAQ
Prev Close 2.09
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.25 / 4.35
Exchange NASDAQ
Shares Outstanding 67.68B
Market Cap 141.44M
Div & Yield N.A. (N.A)
Nymox Announces $850,000 Financing

Nymox Announces $850,000 Financing

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.

Nymox Announces New Prostate Cancer Clinical Trial Results

Nymox Announces New Prostate Cancer Clinical Trial Results

Significantly Better Clinical Outcomes After Up to 2.8 Years for NX-1207 Prostate Cancer Treated Patients Compared to Control Group

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Shares of Nymox Pharmaceuticals (NYMX) were down Monday as investors took profits following four straight days of gains last week in which the stock rose more than 175%.

Nymox Pharmaceutical (NYMX) Surges After Late-Stage Trial Analysis Announcement

Nymox Pharmaceutical (NYMX) Surges After Late-Stage Trial Analysis Announcement

Shares of Nymox Pharmaceutical (NYMX) soared in afternoon trading Thursday after the company announced Wednesday that it would begin further analyses of its Phase 3 studies of NX-1207.

Nymox Announces Phase 3 BPH Studies

Nymox Announces Phase 3 BPH Studies

Nymox Reports 2014 Financial Results

Nymox Reports 2014 Financial Results

4 Stocks Under $10 Making Big Moves Higher

4 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox"...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox"...

Nymox Announces $1.07 Million Financing

Nymox Announces $1.07 Million Financing

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Nymox Pharmaceutical (NYMX) Stock Down After Disappointing Enlarged Prostate Treatment Test Results

Nymox Pharmaceutical (NYMX) Stock Down After Disappointing Enlarged Prostate Treatment Test Results

Nymox (NYMX) shares lost more than 80% of their value today after the company's phase 3 drug trials of its prostate enlargement treatment failed to meet expectations.

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

TheStreet Quant Rating: E+ (Sell)